Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90

Part of paid clinical trials in Palo Alto, California.

Sponsor
Palo Alto Veterans Institute for Research
Study ID
NCT07303712
Status
Recruiting
Apply to this trial

Conditions

  • Hepatocellular Carcinoma (HCC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).

Key Dates

Start date
Aug 1, 2024
Status verified
Oct 2025
Primary completion
Aug 1, 2026
Completion
Dec 1, 2026

Study Design

Enrollment
12 participants (estimated)

Primary Outcome Measure

Circulating Tumor Cell (CTC) [ Time Frame: Baseline, 1 month post treatment, 3 months post treatment, and 6 months post treatment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
VA Palo Alto Health Care SystemPalo AltoCalifornia94304
Sirish Kishore, MD
650-493-5000

Find similar trials in Palo Alto, CA

By research site
VA Palo Alto Health Care System· Palo Alto, CA

Related Studies